Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trial ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory follicular lymphoma (FL).

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.

China’s rapid emergence as a global clinical trials powerhouse will be in sharp focus this September as leading voices from the biopharma and healthcare sectors convene in Suzhou for the launch of ...

The 2025 Clinical Trial Supply West Coast conference will gather experts to discuss US trial operations in a shifting tariff landscape.

RFK Jr’s mRNA funding halt signals “shift in US public health” The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb ...

A rise in gonorrhea infections had been predicted, but if the vaccine reaches vulnerable populations, these are now expected to decline.